Page last updated: 2024-11-04

triazolam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5556
CHEMBL ID646
CHEBI ID9674
SCHEMBL ID29228
MeSH IDM0021910

Synonyms (84)

Synonym
4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-6-(2-chlorophenyl)-1-methyl-
halcion (triazolam)
halcion
u-33030
hypnostat
tgar01h
triazolam
DB00897
D00387
triazolam (jan/usp/inn)
halcion (tn)
28911-01-5
8-chloro-6-(o-chlorophenyl)-1-methyl-4h-s-triazolo[4,3-a][1,4]benzodiazepine
CHEBI:9674 ,
8-chloro-6-(2-chlorophenyl)-1-methyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
ccris 1932
u 33030
dea no. 2887
novidorm
hsdb 6759
triazolamum [inn-latin]
4h-s-triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-(o-chlorophenyl)-1-methyl-
brn 1226643
u-33,030
einecs 249-307-3
8-chloro-6-(2-chlorophenyl)-1-methyl-4h-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine
4h-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-(2-chlorophenyl)-1-methyl-
clorazolam
8-chloro-6-(o-chlorophenyl)-1-methyl-4h-s-triazolo(4,3-a)(1,4)benzodiazepine
songar
NCGC00168258-01
trilam
CHEMBL646 ,
n05cd05
triazolam civ
L000796
bdbm50001765
dtxcid4026763
cas-28911-01-5
tox21_112617
dtxsid6046763 ,
unii-1hm943223r
triazolamum
triazolam [usan:usp:inn:ban:jan]
1hm943223r ,
novodorm
MLS003899243
smr000058837
gtpl7313
triazolam [who-dd]
triazolam civ [usp-rs]
triazolam [usan]
triazolam [orange book]
triazolam [vandf]
triazolam [usp monograph]
triazolam [inn]
triazolam [mart.]
triazolam [jan]
triazolam [hsdb]
triazolam [mi]
u33030
HY-B0694
hypam
8-chloro-1-methyl-6-(o-chlorophenyl)-4h-s-triazolo[4,3-a][1,4]benzodiazepine
8-chloro-6-(2-chlorophenyl)-1-methyl-4h-s-triazolo[4,3-a][1,4]-benzodiazepine
8-chloro-1-methyl-6-(o-chlorophenyl)-4h-s-triazolo-[4,3-a][1,4] benzodiazepine
SCHEMBL29228
12-chloro-9-(2-chlorophenyl)-3-methyl-2,4,5,8-tetraazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),3,5,8,11,13-hexaene
SR-01000937604-2
sr-01000937604
triazolam, european pharmacopoeia (ep) reference standard
triazolam 1.0 mg/ml in methanol
triazolam 0.1 mg/ml in methanol
Q412143
(e)-8-chloro-6-(2-chlorophenyl)-1-methyl-4h-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine
28911-01-5 (free)
8-chloro-6-(2-chlorophenyl)-1-methyl-4h-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine
8-chloro-6-(2-chlorophenyl)-1-methyl-4h-
triazolam (mart.)
triazolam (usp monograph)
triazolam (usan:usp:inn:ban:jan)
triazolam civ (usp-rs)
triazolamum (inn-latin)
triazolam, 1mg/ml in methanol

Research Excerpts

Overview

Triazolam is a benzodiazepine widely prescribed as a hypnotic drug for the treatment of sleep disorders. It appears to be a useful premedicant for surgical patients who wish to have no memory at the operating room.

ExcerptReferenceRelevance
"Triazolam is a benzodiazepine widely prescribed as a hypnotic drug for the treatment of sleep disorders."( Acute intoxication by triazolam and promazine: a case report.
Benucci, G; De Giorgio, F; Fucci, N; Oliva, A; Rossi, R, 2009
)
1.39
"Triazolam appears to be a useful premedicant for surgical patients who wish to have no memory at the operating room."( [Comprehensive evaluation of the effect of triazolam on amnesia during the preoperative period].
Iida, R; Kajiwara, K; Kashiwai, A; Kato, J; Ogawa, S, 2011
)
1.35
"Triazolam, which is a substrate of Cyp3a, was intraperitoneally administered to the mice in the HF group."( Consumption of a high-fat diet during pregnancy decreases the activity of cytochrome P450 3a in the livers of offspring.
Ikarashi, N; Imahori, Y; Ishii, M; Kon, R; Kusunoki, Y; Ochiai, W; Okaniwa, T; Saruta, K; Sugiyama, K; Tajima, M; Toda, T; Yamada, H, 2012
)
1.1
"Triazolam is a short-acting benzodiazepine that results in phase advances of the wheel running activity in hamsters when administered during the mid-subjective day."( MDMA alters the response of the mammalian circadian clock in hamsters: effects on re-entrainment and triazolam-induced phase shifts.
Biello, SM; Blance, RN; Gardani, M, 2005
)
1.27
"Triazolam (T) is a new, potent hypnotic with a short duration of action in man. "( Triazolam disposition.
Eberts, FS; Philopoulos, Y; Reineke, LM; Vliek, RW, 1981
)
3.15
"Triazolam is a triazolobenzodiazepine with hypnotic properties, advocated for use in acute or chronic insomnia, situational insomnia in hospitalised patients, and insomnia associated with other disease states. "( Triazolam: a review of its pharmacological properties and therapeutic efficacy in patients with insomnia.
Avery, GS; Brogden, RN; Heel, RC; Pakes, GE; Speight, TM, 1981
)
3.15
"Triazolam proved to be an effective hypnotic during the six weeks of treatment, with no withdrawal effects upon discontinuation."( [Effects of the chronic administration of triazolam 0.50 mg on the sleep of insomniacs].
Kaffeman, M; Roth, T; Sicklesteel, J; Stepanski, E; Zorick, F, 1982
)
1.25
"Triazolam is a sedative/hypnotic triazolobenzodiazepine, structurally related to alprazolam. "( New drug evaluations. Triazolam.
Juhl, RP; Kroboth, PD,
)
1.89
"Triazolam is a new triazolobenzodiazepine drug that is indicated for the treatment of insomnia. "( Pharmacology and hypnotic efficacy of triazolam.
Roehrs, TA; Roth, T; Zorick, FJ,
)
1.85
"Triazolam was shown to be a reinforcer in four of the six subjects."( Reinforcing effects of triazolam in sedative abusers: correlation of drug liking and self-administration measures.
Henningfield, JE; Jaffe, JH; Klein, S; Meisch, RA; Roache, JD; Sampson, A, 1995
)
1.32
"Triazolam is an effective hypnotic that can cause amnesia and psychomotor performance decrements, particularly after a 0.5 mg dose. "( Design and pharmacodynamic evaluation of novel dual release formulations of triazolam.
Folan, MM; Kroboth, FJ; Kroboth, PD; Rosanske, TW; Smith, RB, 1993
)
1.96
"Triazolam appears to be a safe, effective alternative to parenteral sedation with a benzodiazepine for dental outpatients."( Comparison of oral triazolam and nitrous oxide with placebo and intravenous diazepam for outpatient premedication.
Dionne, RA; Hargreaves, KM; Kaufman, E, 1993
)
1.34
"Triazolam (TZ) is a triazolobenzodiazepine used in the treatment of insomnia that possesses significant anticonvulsant properties. "( Anticonvulsant pharmacodynamics and disposition of triazolam in rats.
Gaudreault, J; Pollack, GM; Varin, F, 1996
)
1.99
"Triazolam is a short-acting benzodiazepine which acts via the GABAA receptor complex."( Acute effects of triazolam in women: relationships with progesterone, estradiol and allopregnanolone.
de Wit, H; Rukstalis, M, 1997
)
1.36
"Triazolam is a high-efficacy benzodiazepine (BZ) agonist, which might be hypothesized to engender highly pharmacologically specific discriminative stimulus (DS) effects and distinguish among BZ agonists with different intrinsic efficacy."( Triazolam discrimination in squirrel monkeys distinguishes high-efficacy agonists from other benzodiazepines and non-benzodiazepine drugs.
Lelas, S; Rowlett, JK; Spealman, RD, 2001
)
3.2
"Triazolam is a very short-acting triazolobenzodiazepine with sedative-hypnotic properties. "( Urinary screening for alpha-OH triazolam by FPIA and EIA with confirmation by GC/MS.
Bryan, W; Fraser, AD; Isner, AF,
)
1.86
"Triazolam appears to be a safe and rapidly acting induction agent in the dog."( The effects of triazolam on cerebral blood flow and metabolism in the dog.
Michenfelder, JD; Roald, OK; Stangland, K; Steen, PA, 1986
)
1.35
"Triazolam apparently acts as an inverse agonist at benzodiazepine receptors expressed on spinal cord cells in culture."( The benzodiazepine triazolam: direct and GABA depressant effects on cultured mouse spinal cord neurons.
Mathers, DA; Yoshida, H, 1987
)
1.32

Effects

Triazolam has a relatively short half-life of about 2 to 3 hours in healthy subjects. It would seem more suitable as an hypnotic than longer acting drugs such as flurazepam or nitrazepam.

Triazolam has been shown to decrease sleep latency and the number of nocturnal awakenings while increasing total sleep time in patients with insomnia. It has an intermediate rate of absorption; due to its ultrashort half-life (1.5 to 5 hours), triazol am is a non-accumulating hypnotic.

ExcerptReferenceRelevance
"As triazolam has a relatively short half-life of about 2 to 3 hours in healthy subjects and has only 1 short acting active metabolite, alpha-hydroxytriazolam, it would seem more suitable as an hypnotic than longer acting drugs such as flurazepam, nitrazepam or flunitrazepam, particularly when residual sedative effects on the day after ingestion are undesirable."( Triazolam: a review of its pharmacological properties and therapeutic efficacy in patients with insomnia.
Avery, GS; Brogden, RN; Heel, RC; Pakes, GE; Speight, TM, 1981
)
2.22
"Triazolam has an intermediate rate of absorption; due to its ultrashort half-life (1.5 to 5 hours), triazolam is a non-accumulating hypnotic."( Pharmacokinetic properties of benzodiazepine hypnotics.
Abernethy, DR; Divoll, M; Greenblatt, DJ; Harmatz, JS; Shader, RI, 1983
)
0.99
"Triazolam has an intermediate absorption rate, but is rapidly eliminated (half-life 1.5-5 h) making it essentially non-accumulating."( Pharmacokinetics of benzodiazepine hypnotics.
Abernethy, DR; Divoll, M; Greenblatt, DJ; Locniskar, A; Shader, RI, 1983
)
0.99
"Triazolam has an intermediate absorption rate, but is rapidly eliminated (half-life 1.5-5 h) making it essentially non-accumulating."( Pharmacokinetics of benzodiazepine hypnotics.
Abernethy, DR; Divoll, M; Greenblatt, DJ; Locniskar, A; Shader, RI, 1982
)
0.99
"Triazolam reportedly has greater amnesic potential than other benzodiazepines. "( [Comprehensive evaluation of the effect of triazolam on amnesia during the preoperative period].
Iida, R; Kajiwara, K; Kashiwai, A; Kato, J; Ogawa, S, 2011
)
2.07
"Triazolam has not been shown to be carcinogenic, and it has a low potential for abuse and addiction."( Oral triazolam sedation in implant dentistry.
Flanagan, D, 2004
)
1.56
"1. Triazolam (TRZ) has been used extensively in rat to evaluate its benzodiazepine agonist central nervous system effects. "( Role of CYP3A enzymes in the biotransformation of triazolam in rat liver.
Greenblatt, DJ; Von Moltke, LL; Warrington, JS, 2004
)
1.2
"As triazolam has a relatively short half-life of about 2 to 3 hours in healthy subjects and has only 1 short acting active metabolite, alpha-hydroxytriazolam, it would seem more suitable as an hypnotic than longer acting drugs such as flurazepam, nitrazepam or flunitrazepam, particularly when residual sedative effects on the day after ingestion are undesirable."( Triazolam: a review of its pharmacological properties and therapeutic efficacy in patients with insomnia.
Avery, GS; Brogden, RN; Heel, RC; Pakes, GE; Speight, TM, 1981
)
2.22
"Triazolam has an intermediate rate of absorption; due to its ultrashort half-life (1.5 to 5 hours), triazolam is a non-accumulating hypnotic."( Pharmacokinetic properties of benzodiazepine hypnotics.
Abernethy, DR; Divoll, M; Greenblatt, DJ; Harmatz, JS; Shader, RI, 1983
)
0.99
"Triazolam has been shown to decrease sleep latency and the number of nocturnal awakenings while increasing total sleep time in patients with insomnia."( New drug evaluations. Triazolam.
Juhl, RP; Kroboth, PD,
)
1.17
"For triazolam, which has higher hepatic clearance and an intermediate extraction ratio, total clearance was reduced by cimetidine (3.9 versus 5.9 ml/min/kg), causing a significant increase in total area under the plasma concentration curve (25 versus 38 ng/ml X h, P less than 0.02)."( Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam.
Abernethy, DR; Divoll, M; Greenblatt, DJ; Harmatz, JS; Moschitto, LJ; Shader, RI, 1983
)
0.98
"Triazolam has an intermediate absorption rate, but is rapidly eliminated (half-life 1.5-5 h) making it essentially non-accumulating."( Pharmacokinetics of benzodiazepine hypnotics.
Abernethy, DR; Divoll, M; Greenblatt, DJ; Locniskar, A; Shader, RI, 1983
)
0.99
"Triazolam has an intermediate absorption rate, but is rapidly eliminated (half-life 1.5-5 h) making it essentially non-accumulating."( Pharmacokinetics of benzodiazepine hypnotics.
Abernethy, DR; Divoll, M; Greenblatt, DJ; Locniskar, A; Shader, RI, 1982
)
0.99
"Triazolam has been a controversial drug since its appearance on world markets as a hypnotic more than ten years ago. "( Triazolam blood concentrations in forensic cases in Canada.
Joynt, BP,
)
3.02
"Triazolam has shown promise as a sedative agent for use in pediatric dentistry. "( A randomized clinical trial of triazolam in 3- to 5-year-olds.
Coldwell, SE; Kaakko, T; Karl, HW; Milgrom, P; Perkis, V; Raadal, M; Weinstein, P, 1999
)
2.03
"Triazolam has also been found to facilitate the rate of reentrainment of the activity rhythm following an 8-hour advance or delay in the light-dark cycle."( Use of benzodiazepines to manipulate the circadian clock regulating behavioral and endocrine rhythms.
Turek, FW; Van Reeth, O, 1989
)
1

Actions

Triazolam was chosen because of its short half-life of 2.5 hours. It failed to produce statistically significant phase shifts when administered during the subjective day. It did not increase the duration or improve the continuity of sleep during the 8-h flight from the U.S.

ExcerptReferenceRelevance
"Triazolam was chosen because of its short half-life of 2.5 hours."( [Saccadic eye movements as a measure of the pharmacodynamics of benzodiazepines. Evaluation of various occulographic parameters].
Fisch, HU; Meienberg, O; Schlaginhaufen, W, 1984
)
0.99
"Triazolam failed to produce statistically significant phase shifts when administered during the subjective day, but 2 animals bearing functional SCN grafts responded to this benzodiazapine during the subjective night."( Regulation of the phase and period of circadian rhythms restored by suprachiasmatic transplants.
Basil, J; Bittman, EL; Jetton, AE; Lehman, MN; Matsumoto, S, 1996
)
1.02
"Triazolam may cause cognitive dysfunction without general sedation or apparent sleepiness, and this effect appeared 2 h, 4 h and 6 h, most prominently 6 h, after TRZ administration."( Effects of a small dose of triazolam on P300.
Enomoto, T; Hayakawa, T; Okawa, M; Okubo, J; Uchiyama, M; Urata, J, 1999
)
1.32
"Triazolam did not produce evidence of tolerance development after 2 weeks of treatment."( Multi-clinic double-blind comparison of triazolam (Halcion) and placebo administered for 14 consecutive nights in outpatients with insomnia.
Brachfeld, J; Calvo, R; Fabre, LF; Metzler, C; Meyer, LR; Slowe, IA, 1978
)
1.25
"Triazolam did not produce reinforcing or aversive effects when administered in doses ranging from 0.0625 to 0.5 mg/kg."( Triazolam attenuates amphetamine but not morphine conditioned place preferences.
Batsell, WR; Mueller, K; Pettit, HO, 1989
)
2.44
"Triazolam did not increase the duration or improve the continuity of sleep during the 8-h flight from the U.S."( Triazolam impairs learning and fails to improve sleep in a long-range aerial deployment.
Belenky, G; Garrigan, JJ; Penetar, DM; Redmond, DP, 1989
)
2.44
"Triazolam caused an increase in breathing frequency (+21% to 50%; p less than 0.05) as a result of a shortening of inspiratory time."( Ventilatory effects of single, high-dose triazolam in awake human subjects.
Begle, RL; Busch, MA; Skatrud, JB, 1988
)
1.26
"Triazolam did not enhance the depressions evoked by adenosine 5'-N-ethylcarboxamide, an uptake resistant analog of adenosine, suggesting that potentiation of adenosine resulted from an inhibition of adenosine uptake."( Potentiation of adenosine-evoked depression of rat cerebral cortical neurons by triazolam.
O'Regan, MH; Phillis, JW, 1988
)
1.22

Treatment

Triazolam pretreatment did not significantly attenuate the subject-rated effects of cocaine. With triazolAm pretreatment, both the VAS and ISAR scores decreased significantly. Trizolam-treated patients presented significantly more day-time-interdose anxiety than zopiclone.

ExcerptReferenceRelevance
"Triazolam pretreatment did not significantly attenuate the subject-rated effects of cocaine."( Behavioral and physiological effects of cocaine in humans following triazolam.
Baker, RW; Haga, JL; Rush, CR, 2003
)
1.28
"With triazolam pretreatment, both the VAS and ISAR scores decreased significantly."( Oral triazolam pretreatment for intravenous sedation.
Finder, RL; McGirl, BE; Moore, PA; Stopperich, PS; Weyant, RJ, 1993
)
1.26
"Triazolam treatment showed superior immediate treatment effects, while behavioral treatment showed superior treatment effects at follow-up, effects that accrued during the training period and differentially persisted at follow-up. "( Efficacy of behavioral versus triazolam treatment in persistent sleep-onset insomnia.
McClusky, HY; Milby, JB; Switzer, PK; Williams, V; Wooten, V, 1991
)
2.01
"Triazolam-treated patients showed subsequent improvement on the tests, consistent with practice effects, whereas flurazepam recipients showed performance impairment during treatment."( Differential side effect profile of triazolam versus flurazepam in elderly patients undergoing rehabilitation therapy.
Greenblatt, DJ; Proulx, SM; Woo, E, 1991
)
1.28
"Triazolam-treated patients presented significantly more day-time-interdose anxiety than zopiclone as assessed by the weekly HARS and Clinical Global Assessment of Anxiety."( Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety.
Beauclair, L; Beaudry, P; Chouinard, G; Fontaine, R; Le Morvan, P, 1990
)
1.36
"Triazolam-treated hamsters became ataxic in all three of these experiments."( Triazolam and phase-shifting acceleration re-evaluated.
Mrosovsky, N; Salmon, PA, 1990
)
2.44

Toxicity

No clinically significant adverse reactions were encountered. No adverse reactions occurred more frequently in the triazolam group than in the placebo group. Although some studies showed the possibility of adverse effects of trizolam in older people, there have been few studies investigating these effects in a clinical setting.

ExcerptReferenceRelevance
"Findings from a four-city study of the beneficial and adverse effects of hypnotics are reported."( The beneficial and adverse effects of hypnotics.
Balter, MB; Uhlenhuth, EH, 1991
)
0.28
" No clinically significant adverse reactions were encountered and no adverse reactions occurred more frequently in the triazolam group than in the placebo group."( Hypnotic efficacy and safety of triazolam administered during the postoperative period.
Holland, JC; Jacobsen, PB; Kinne, DW; Massie, MJ, 1994
)
0.78
" Analyses of post-marketing surveillance and a database of all spontaneously reported adverse events were also evaluated."( The safety of ranitidine in over a decade of use.
Fitzgerald, K; Koch, KM; Mills, JG; Sirgo, MA; Webster, C; Wood, JR, 1997
)
0.3
"Overall in the clinical trial programme adverse events were reported by 20% of those receiving ranitidine compared with 27% of those receiving placebo."( The safety of ranitidine in over a decade of use.
Fitzgerald, K; Koch, KM; Mills, JG; Sirgo, MA; Webster, C; Wood, JR, 1997
)
0.3
"Review of data from a large population of controlled clinical trials with analyses of postmarketing surveillance studies and spontaneously reported adverse events confirmed the excellent safety profile of ranitidine."( The safety of ranitidine in over a decade of use.
Fitzgerald, K; Koch, KM; Mills, JG; Sirgo, MA; Webster, C; Wood, JR, 1997
)
0.3
" It is argued that regulators and the medical profession rely too heavily on manufacturers to investigate warnings from doctors' spontaneous reporting of adverse effects of drug products on the market."( Transnational industrial power, the medical profession and the regulatory state: adverse drug reactions and the crisis over the safety of Halcion in the Netherlands and the UK.
Abraham, J, 2002
)
0.31
"Many adverse drug reactions are caused by the cytochrome P450 (CYP) dependent activation of drugs into reactive metabolites."( An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics.
Grossi, P; Kanter, Rd; Monaci, S; Monshouwer, M; Turlizzi, E; Vignati, L, 2005
)
0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Most serious adverse events are related to potentially avoidable respiratory complications."( Balancing efficacy and safety in the use of oral sedation in dental outpatients.
Coté, CJ; Dionne, RA; Donaldson, M; Edwards, M; Greenblatt, DJ; Haas, D; Malviya, S; Milgrom, P; Moore, PA; Shampaine, G; Silverman, M; Williams, RL; Wilson, S; Yagiela, JA, 2006
)
0.33
"Safety in outpatient sedation is of paramount concern, with enteral administration of benzodiazepines appearing safe but poorly documented in the office setting."( Balancing efficacy and safety in the use of oral sedation in dental outpatients.
Coté, CJ; Dionne, RA; Donaldson, M; Edwards, M; Greenblatt, DJ; Haas, D; Malviya, S; Milgrom, P; Moore, PA; Shampaine, G; Silverman, M; Williams, RL; Wilson, S; Yagiela, JA, 2006
)
0.33
" Anonymous treatment forms with monitoring records were collected from respondents and analyzed for pre-specified adverse event criteria."( Evidence of safety for individualized dosing of enteral sedation.
Dionne, RA; Gordon, SM; Shimizu, N; Shlash, D,
)
0.13
" Primary outcomes were patient-reported pain relief ≥ 30% and withdrawals due to adverse events."( The efficacy and safety of muscle relaxants in inflammatory arthritis: a Cochrane systematic review.
Buchbinder, R; Richards, BL; van der Heijde, DM; Whittle, SL, 2012
)
0.38
" Data from 2 trials of longer than 24-hour duration (diazepam and zopiclone, n = 74) found that participants who received a muscle relaxant had significantly more adverse events compared with those who received placebo [number needed to harm (NNTH) 3, 95% CI 2 to 7]."( The efficacy and safety of muscle relaxants in inflammatory arthritis: a Cochrane systematic review.
Buchbinder, R; Richards, BL; van der Heijde, DM; Whittle, SL, 2012
)
0.38
" However, even short-term muscle relaxant use (24 hours to 2 weeks) is associated with significant adverse events, predominantly drowsiness and dizziness."( The efficacy and safety of muscle relaxants in inflammatory arthritis: a Cochrane systematic review.
Buchbinder, R; Richards, BL; van der Heijde, DM; Whittle, SL, 2012
)
0.38
" Although some studies showed the possibility of adverse effects of triazolam in older people, there have been few studies investigating these effects in a clinical setting."( Quantification of adverse effects of regular use of triazolam on clinical outcomes for older people with insomnia: a retrospective cohort study.
Babazono, A; Maeda, T; Nishi, T; Yasui, M, 2016
)
0.92

Pharmacokinetics

Triazolam's apparent elimination half-life after evening administration was significantly longer than after daytime ingestion. Age had no significant effect on area under the trizolam plasma concentration curve (AUC)

ExcerptReferenceRelevance
" These results indicate that no pharmacokinetic interaction exists between triazolam and fluoxetine or norfluoxetine."( A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine.
Lasher-Sisson, TA; Steenwyk, RC; Swanson, CN; Wright, CE, 1992
)
0.75
" When dialysis patients took triazolam with 3600 mg aluminum hydroxide suspension, Cmax and AUC were increased into the range observed in control subjects."( Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.
Juhl, RP; Kroboth, PD; Puschett, JB; Rault, R; Silver, MR; Smith, RB; Sorkin, MI, 1985
)
0.8
" Moreover, for triazolam, the C max was increased and the plasma elimination half-life was prolonged; oral clearance of the two triazolobenzodiazepines was markedly reduced."( Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects.
Desager, JP; Harvengt, C; Hulhoven, R; Pourbaix, S; Smith, RB, 1985
)
0.83
" The time-course of effects on memory and psychomotor performance were related to triazolam plasma concentration profile using an Emax model for effect and a two-compartment pharmacokinetic model."( Pharmacodynamics of triazolam after intravenous administration.
Kroboth, PD; Smith, RB; Varner, PD, 1987
)
0.82
" There was a significant enhancement of the AUC, the peak concentration and the delay to tmax of triazolam after 7 days treatment with troleandomycin compared to placebo."( Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation.
Bensimon, G; Bergougnan, L; Berlin, I; Danjou, P; Lamiable, D; Puech, AJ; Warot, D, 1987
)
0.84
"73 ng ml-1), the time of peak concentration (0."( Lack of influence of cigarette smoking on triazolam pharmacokinetics.
Burstein, ES; Greenblatt, DJ; Ochs, HR, 1987
)
0.54
" Triazolam's apparent elimination half-life after evening administration was significantly longer than after daytime ingestion (3."( Temporal variation in triazolam pharmacokinetics and pharmacodynamics after oral administration.
Kroboth, PD; Phillips, JP; Smith, RB, 1986
)
1.5
" Mean triazolam elimination half-life was not significantly different between young and elderly men (3."( Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity.
Abernethy, DR; Divoll, M; Greenblatt, DJ; Moschitto, LJ; Shader, RI; Smith, RB, 1983
)
1.07
" The pharmacokinetic properties of these newer drugs can best be understood by their categorisation according to range of elimination half-life and pathway of metabolism (oxidation versus conjugation)."( Clinical pharmacokinetics of the newer benzodiazepines.
Abernethy, DR; Divoll, M; Greenblatt, DJ; Ochs, HR; Shader, RI,
)
0.13
"6 hours), elimination half-life (2."( Pharmacokinetic noninteraction of triazolam and ethanol.
Arendt, RM; Greenblatt, DJ; Hübbel, W; Ochs, HR; Shader, RI, 1984
)
0.55
" However, if given once-daily it still would not accumulate with long term dosing due to its short half-life relative to the interval between doses."( The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam.
Abernethy, DR; Divoll, M; Greenblatt, DJ; Shader, RI; Smith, RB,
)
0.36
" Previous pharmacodynamic studies suggested a relationship between these effects and triazolam plasma concentration."( Design and pharmacodynamic evaluation of novel dual release formulations of triazolam.
Folan, MM; Kroboth, FJ; Kroboth, PD; Rosanske, TW; Smith, RB, 1993
)
0.74
" Our findings show that there were no significant differences between the patients with cirrhosis and the control subjects in any of the pharmacokinetic parameters."( Triazolam in cirrhosis: pharmacokinetics and pharmacodynamics.
Hasan, SS; Lee, M; Robin, DW; Wood, AJ, 1993
)
1.73
" In all studies, blood samples were also obtained at testing times so that effect/concentration comparisons could be made and so full pharmacokinetic analyses could be done for separate studies."( Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment.
Barbhaiya, R; Chaikin, PC; Folan, MM; Kroboth, PD; Lush, RM; Salazar, DE; Shukla, UA, 1995
)
0.29
" Noncompartmental pharmacokinetic analysis showed that there was no effect of triazolam on the pharmacokinetics of nefazodone, HO-nefazodone, or mCPP after the coadministration of triazolam and nefazodone."( Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam.
Barbhaiya, RH; Greene, DS; Kroboth, PD; Shukla, UA, 1995
)
0.74
"The purpose of this study was to determine the pharmacokinetic behavior of triazolam in children."( Pharmacokinetics of oral triazolam in children.
Awamura, K; Coldwell, SE; Domoto, P; Karl, HW; Kharasch, ED; Leroux, B; Mautz, D; Milgrom, P; Weinstein, P, 1997
)
0.83
" The means +/- standard deviation of the peak plasma concentration, the total area under the plasma concentration-time curve and the elimination half-life of alprazolam were 11."( Relationship between single oral dose pharmacokinetics of alprazolam and triazolam.
Furukori, H; Hayashi, K; Kaneko, S; Nagasaki, T; Ohkubo, T; Otani, K; Sugawara, K; Tasaki, H; Yasui, N, 1997
)
0.53
" There were no significant differences in plasma concentrations from 20 minutes to 6 hours after the dosing nor in pharmacokinetic parameters of triazolam between the EM and PM groups."( Single-dose pharmacokinetics and pharmacodynamics of oral triazolam in relation to cytochrome P4502C19 (CYP2C19) activity.
Chiba, K; Ishizaki, T; Kaneko, S; Ohkubo, T; Osanai, T; Otani, K; Sugawara, K; Yasui, N, 1997
)
0.74
" Despite significant elevations in triazolam plasma levels with coadministration of ketoconazole, the pharmacodynamic enhancement was lower than predicted based on plasma levels of triazolam."( Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice.
Fahey, JM; Grassi, JM; Greenblatt, DJ; Moltke, LL; Pratt, JS; Pritchard, GA; Shader, RI, 1998
)
0.87
" Plasma concentrations and pharmacodynamic parameters were measured after each dose."( Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences.
Corbett, K; Counihan, M; Ehrenberg, BL; Greenblatt, DJ; Harmatz, JS; Harrel, LM; Shader, RI; Tobias, S; von Moltke, LL; Wright, CE, 1998
)
0.6
"002) and apparent elimination half-life (t1/2) prolonged (59 versus 15 hours; P < ."( Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences.
Corbett, K; Counihan, M; Ehrenberg, BL; Greenblatt, DJ; Harmatz, JS; Harrel, LM; Shader, RI; Tobias, S; von Moltke, LL; Wright, CE, 1998
)
0.6
" The actual interactions, and their pharmacodynamic consequences, were verified in a controlled clinical study."( Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences.
Counihan, M; Duan, SX; Durol, AL; Graf, JA; Greenblatt, DJ; Harmatz, JS; Mertzanis, P; Shader, RI; von Moltke, LL; Wright, CE, 1998
)
0.66
"32 ng/mL) and elimination half-life (2."( Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences.
Counihan, M; Duan, SX; Durol, AL; Graf, JA; Greenblatt, DJ; Harmatz, JS; Mertzanis, P; Shader, RI; von Moltke, LL; Wright, CE, 1998
)
0.66
" Anticipated interactions, and their pharmacodynamic consequences in volunteer subjects, were verified in vivo."( Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences.
Counihan, M; Duan, SX; Durol, AL; Graf, JA; Greenblatt, DJ; Harmatz, JS; Mertzanis, P; Shader, RI; von Moltke, LL; Wright, CE, 1998
)
0.66
" The Medline electronic database from 1966 through 1998 was used to identify clinical studies of the pharmacokinetic effect of drugs on these three benzodiazepines."( Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam.
Balian, JD; Flockhart, DA; Yuan, R, 1999
)
0.51
"005), prolonged elimination half-life (41 versus 3 hours; p < ."( Differential impairment of triazolam and zolpidem clearance by ritonavir.
Daily, JP; Durol, AL; Graf, JA; Greenblatt, DJ; Harmatz, JS; Hoffman, JL; Mertzanis, P; Shader, RI; von Moltke, LL, 2000
)
0.6
" There were no changes in the half-life of triazolam or alpha-hydroxytriazolam."( Effect of ranitidine on the pharmacokinetics of triazolam and alpha-hydroxytriazolam in both young (19-60 years) and older (61-78 years) people.
Kersey, K; Koch, KM; Lam, R; O'Connor-Semmes, RL; Williams, DH, 2001
)
0.83
" Pharmacokinetic profiles for ethinyl estradiol and for a single oral dose of triazolam (0."( Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers.
Arora, S; Hellriegel, ET; Nelson, M; Robertson, P, 2002
)
0.78
" The half-life of triazolam was also decreased, but the half-life of ethinyl estradiol did not appear to be affected by treatment with modafinil."( Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers.
Arora, S; Hellriegel, ET; Nelson, M; Robertson, P, 2002
)
0.88
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
" Among women, age had no significant effect on area under the triazolam plasma concentration curve (AUC) (Spearman r=0."( Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate.
Greenblatt, DJ; Harmatz, JS; Shader, RI; von Moltke, LL; Wright, CE, 2004
)
0.8
" Pharmacodynamic effects were measured by DSST and EEG at corresponding times."( Pharmocokinetics and pharmacodynamics of single-dose triazolam: electroencephalography compared with the Digit-Symbol Substitution Test.
Gan, L; Greenblatt, DJ; Harmatz, JS; Shader, RI, 2005
)
0.58
" However, the variations in area under the curve of pharmacodynamic effect vs."( Pharmocokinetics and pharmacodynamics of single-dose triazolam: electroencephalography compared with the Digit-Symbol Substitution Test.
Gan, L; Greenblatt, DJ; Harmatz, JS; Shader, RI, 2005
)
0.58
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Plasma triazolam concentrations increased with time in all subjects, with Tmax and Cmax both increasing dose dependently."( Expanded studies of the pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers.
Heima, M; Hosaka, K; Jackson, DL; Kharasch, E; Milgrom, PM; Pickrell, JE, 2009
)
1.01
"Itraconazole is a potent inhibitor of cytochrome P450 (CYP) 3A with an elimination half-life of more than 30 hours."( Pharmacokinetic modeling of the dosing interval dependency for the interaction between itraconazole and triazolam.
Ohtani, H; Sawada, Y; Toi, A; Tsujimoto, M, 2010
)
0.58
"We developed a pharmacokinetic model based on the assumption that both itraconazole and hydroxyitraconazole competitively and reversibly inhibit the first-pass metabolism and systemic elimination of triazolam."( Pharmacokinetic modeling of the dosing interval dependency for the interaction between itraconazole and triazolam.
Ohtani, H; Sawada, Y; Toi, A; Tsujimoto, M, 2010
)
0.76
"The objective of this study was to evaluate the pharmacokinetic and pharmacodynamic interactions between the oral adsorbent AST-120 and triazolam."( Effects of dosing interval on the pharmacokinetic and pharmacodynamic interactions between the oral adsorbent AST-120 and triazolam in humans.
Imai, H; Kotegawa, T; Morita, H; Morita, M; Namiki, N; Ohashi, K; Ohyama, T; Tsutsumi, K; Uchida, S; Watanabe, H; Yoshizato, T, 2012
)
0.79
" No significant changes in pharmacokinetic and pharmacodynamic parameters were observed when AST-120 was given 30 or 60 min before triazolam administration."( Effects of dosing interval on the pharmacokinetic and pharmacodynamic interactions between the oral adsorbent AST-120 and triazolam in humans.
Imai, H; Kotegawa, T; Morita, H; Morita, M; Namiki, N; Ohashi, K; Ohyama, T; Tsutsumi, K; Uchida, S; Watanabe, H; Yoshizato, T, 2012
)
0.79
"This paper addresses the pharmacokinetic properties of eszopiclone and the extent to which the longer half-life of eszopiclone compared to other commonly used hypnotics (immediate-release zolpidem, modified-release zolpidem, triazolam, zaleplon) may translate into either improved efficacy in enhancing sleep maintenance, or increased probability of residual sedative or performance-impairing effects."( Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications.
Greenblatt, DJ; Zammit, GK, 2012
)
0.56
" The mean half-life in healthy nonelderly individuals (6."( Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications.
Greenblatt, DJ; Zammit, GK, 2012
)
0.38
" A physiologically based pharmacokinetic (PBPK) model was developed to project the dynamics and magnitude of CYP3A4 induction in vivo from in vitro data generated with primary human hepatocytes."( Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.
Baneyx, G; Iliadis, A; Lavé, T; Meille, C; Parrott, N, 2014
)
0.4
"This validated LC-MS/MS method using DBS extraction was applied to quantitation of TRZ, α-hydroxytriazolam and 4-hydroxytriazolam in a CYP3A4 transgenic mouse oral pharmacokinetic study of TRZ."( LC-MS determination of triazolam and its hydroxy metabolites in mouse dried blood spots: application to transgenic mouse pharmacokinetic studies.
Kole, P; Kurawattimath, V; Mandlekar, S; Rao, A, 2017
)
0.98

Compound-Compound Interactions

ExcerptReferenceRelevance
"Two benzodiazepine hypnotics were administered alone or in combination with alcohol to normal male volunteers."( A comparison of two benzodiazepine hypnotics administered with alcohol.
Goodwin, DW; Hill, SY; Hopper, S; Mendelson, WB; Reichman, JB, 1982
)
0.26
"Ten expressed human CYPs and human liver microsomes were used in the experiments for the identification of enzymes responsible for zonisamide metabolism and for the prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data, respectively."( Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data.
Kitada, M; Kiuchi, M; Nakamura, H; Nakasa, H; Ohmori, S; Ono, S; Tsutsui, M, 1998
)
0.3
"We demonstrated that: (1) zonisamide is metabolized by recombinant CYP3A4, CYP2C19 and CYP3A5, (2) the metabolism is inhibited to a variable extent by known CYP3A4/5 substrates and/or inhibitors in human liver microsomes, and (3) in vitro-in vivo predictive calculations suggest that several compounds demonstrating CYP3A4-affinity might cause in vivo drug-drug interactions with zonisamide."( Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data.
Kitada, M; Kiuchi, M; Nakamura, H; Nakasa, H; Ohmori, S; Ono, S; Tsutsui, M, 1998
)
0.3
" The method was applied to drug-drug interaction study of TZ with itraconazole (ITZ)."( Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole.
Al-Dirbashi, OY; Kaddoumi, A; Nakashima, K; Nakashima, MN; Yamamoto, K, 2003
)
0.62
"To predict the magnitude of metabolic drug-drug interaction (mDDI) between triazolam and diltiazem and its primary metabolite N-desmethyldiltiazem (MA)."( Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time
Jamei, M; Rostami-Hodjegan, A; Rowland Yeo, K; Tucker, GT; Yang, J, 2010
)
0.59
"The induction of cytochrome P450 (P450) enzymes is one of the risk factors for drug-drug interactions (DDIs)."( Investigation of drug-drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver.
Hasegawa, M; Inoue, R; Kakuni, M; Tahara, H; Tateno, C; Ushiki, J, 2012
)
0.38
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
" While grapefruit juice has been extensively studied with respect to its drug-drug interaction potential, numerous other fruit juices such as cranberry juice, orange juice, grape juice, pineapple juice and pomegranate juice have also been investigated for its potential to show drug-drug interaction of any clinical relevance."( Is pomegranate juice a potential perpetrator of clinical drug-drug interactions? Review of the in vitro, preclinical and clinical evidence.
Srinivas, NR, 2013
)
0.39
" The new model is useful for estimating the risk of drug interaction in clinical practice when AST-120 is used in combination with other drugs."( Prediction of drug interaction between oral adsorbent AST-120 and concomitant drugs based on the in vitro dissolution and in vivo absorption behavior of the drugs.
Kotegawa, T; Koya, Y; Machi, Y; Namiki, N; Shobu, Y; Uchida, S, 2016
)
0.43

Bioavailability

The bioavailability of triazolam after sublingual administration is increased by an average of 28% compared with oral administration of the same dose. First-pass extraction is bypassed.

ExcerptReferenceRelevance
" Bioavailability in terms of area under the plasma concentration versus time curve (AUC0 infinity), maximum plasma concentration (Cmax), time to maximum (tmax), and mean residence time (MRT) was not statistically significantly different from one formulation to the other."( Bioavailability of two oral formulations of triazolam using radioreceptor assay.
Cepeláková, H; Franc, Z; Lapka, R; Rejholec, V, 1986
)
0.53
" Thus, the bioavailability of triazolam after sublingual administration is increased by an average of 28% compared with oral administration of the same dose, possibly because first-pass extraction is bypassed."( Enhanced bioavailability of triazolam following sublingual versus oral administration.
Friedman, H; Greenblatt, DJ; Scavone, JM; Shader, RI, 1986
)
0.85
" Temazepam has a relatively slow rate of absorption and an intermediate half-life in the range of 10 to 20 hours."( Pharmacokinetic properties of benzodiazepine hypnotics.
Abernethy, DR; Divoll, M; Greenblatt, DJ; Harmatz, JS; Shader, RI, 1983
)
0.27
" Inter-individual variability in absorption rate (peak times) was larger for brotizolam."( Comparative pharmacokinetics of brotizolam and triazolam in healthy subjects.
Breimer, DD; Hermans, J; Jochemsen, R; van Boxtel, CJ; Wesselman, JG, 1983
)
0.52
"The onset and duration of action of benzodiazepines after single oral doses depend largely on absorption rate and the rate and extent of distribution."( [Benzodiazepines: significance of kinetics for therapy].
Ochs, HR, 1983
)
0.27
"Grapefruit juice increases the bioavailability of several drugs known to be metabolized by CYP3A enzymes."( Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.
Hukkinen, SK; Neuvonen, PJ; Olkkola, KT; Varhe, A, 1995
)
0.59
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
" The main reason for the difference appears to be due to differences in the rate of absorption of the main drug."( [Comparative study of drug efficacy and drug additives between generic drugs and original drugs].
Katoh, H; Ozawa, K; Yoshii, M, 2007
)
0.34
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" Hepatic biotransformation of 1α,25(OH)(2)D(3) by cytochrome P450 (P450) enzymes could be an important determinant of bioavailability in serum and tissues."( Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
Adomat, H; Deb, S; Guns, ES; Pandey, M, 2012
)
0.38
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Triazolam should be reduced on average by 50 percent for elderly people, according to this study. The daily dosage ranged from 5 to 15 mg (100-300 mg diazepam equivalent) and the duration of use ranged from 3 months to 5 years.

ExcerptRelevanceReference
" The dosage was doubled after nights 2 and 9 if good sleep was not produced."( Multi-clinic cross-over comparison of triazolam (Halcion) and placebo in the treatment of co-existing insomnia and anxiety in anxious out-patients.
Fabre, LF; Smith, WT, 1977
)
0.53
" Some interesting theoretical and practical questions about the measurement of sustained efficacy of hypnotics in situations of repetitive dosing were addressed by the study."( Methodology for demonstrating sustained efficacy of hypnotics: a comparative study of triazolam and flurazepam.
Lasagna, L; Sundaresan, PR; Wardell, WM; Weintraub, M, 1979
)
0.48
" and 1 h after oral dosing of [14C]triazolam to rats."( Metabolism of 8-chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo [4,3-alpha] [1,4] benzodiazepine, triazolam, a new central depressant. I. Absorption, distribution and excretion in rats, dogs and monkeys.
Esumi, Y; Kitagawa, H; Kurosawa, S; Sekine, S; Yokoshima, T, 1979
)
0.75
" Major metabolites in the urine, faeces, plasma and brain after 7-, 14- or 21-day repeated dosing in rats were not much different in type and ratio from those after single dosing."( Metabolism of 8-chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo [4,3-alpha] [1,4]benzodiazepine, triazolam, a new central depressant. II. Identification and determination of metabolites in rats and dogs.
Esumi, Y; Kitagawa, H; Kurosawa, S; Sekine, S; Yokoshima, T, 1979
)
0.48
" We report five cases of high-dose triazolam abuse in which the daily dosage ranged from 5 to 15 mg (100-300 mg diazepam equivalent) and the duration of use ranged from 3 months to 5 years."( Detoxification for triazolam physical dependence.
Sellers, EM; Sullivan, JT, 1992
)
0.89
" Comparison of the dose-response curves demonstrated a difference in the intensity of the stimulus effects."( The discriminative stimulus effects of diazepam in rats at two training doses.
Franklin, SR; Tang, AH, 1991
)
0.28
" The signal perceived by the NARD appears to have been a valuable warning, rightly casting doubt on the safety of triazolam and the original dosage recommendations."( [Secondary effects of drugs. The 1979 Halcion experience in the Netherlands, a false alarm?].
Meyboom, RH,
)
0.34
" Plasma concentrations for each hypnotic after dosing were measured by electron-capture gas-liquid chromatography."( Intranasal absorption of flurazepam, midazolam, and triazolam in dogs.
Amidon, GL; Goldberg, A; Lui, CY, 1991
)
0.53
" Results indicated that performance and alertness in all nap conditions were improved in a dose-response fashion compared to a no-nap control throughout the first 24 hr of sleep loss."( The effect of varying prophylactic naps on performance, alertness and mood throughout a 52-hour continuous operation.
Bonnet, MH, 1991
)
0.28
" On the basis of these results, the dosage of triazolam for elderly persons should be reduced on average by 50 percent."( Sensitivity to triazolam in the elderly.
Engelhardt, N; Gouthro, TA; Greenblatt, DJ; Harmatz, JS; Shader, RI; Shapiro, L, 1991
)
0.89
" The signal perceived by the NARD appears to have been a valuable warning, rightly casting doubt on the safety of triazolam and the original dosage recommendations."( [The Halcion affair in 1979, a false alarm?].
Meyboom, RH, 1989
)
0.49
"5 hours by oral ethanol dosed to maintain breath concentrations of 800 to 950 mg/L; placebo and ethanol; and triazolam and orange juice."( Triazolam and ethanol interaction: kinetic and dynamic consequences.
Abernethy, D; Dorian, P; Greenblatt, DJ; Hamilton, C; Kaplan, HL; Sellers, EM, 1985
)
1.92
" It is suggested that the combined treatment cimetidine-alprazolam requires a reduced daily dosage (one third) of alprazolam or increased dosage intervals (b."( Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects.
Desager, JP; Harvengt, C; Hulhoven, R; Pourbaix, S; Smith, RB, 1985
)
0.48
"The respiratory-depressant effect of the benzodiazepine-derived hypnotic triazolam was investigated with a single oral dose at two and three times the usual dosage in 62 awake normal subjects."( Ventilatory effects of single, high-dose triazolam in awake human subjects.
Begle, RL; Busch, MA; Skatrud, JB, 1988
)
0.77
"Triazolam pharmacokinetics and effects on sedation, short-term amnesia, and psychomotor performance were evaluated in 25 normal volunteers as part of a safety and tolerance study of intravenous dosing of triazolam."( Pharmacodynamics of triazolam after intravenous administration.
Kroboth, PD; Smith, RB; Varner, PD, 1987
)
2.04
" In contrast, triazolam dosing did not significantly improve any of the major sleep efficiency parameters, and there was a rapid development of tolerance for the drug's slight initial effectiveness."( Comparison of short and long half-life benzodiazepine hypnotics: triazolam and quazepam.
Bixler, EO; Kales, A; Manfredi, RL; Niklaus, DE; Soldatos, CR; Vela-Bueno, A, 1986
)
0.87
" Six subjects received 80 mg DZ every third day (3 subjects) or every sixth day (3 subjects) for a total of 3-6 dosing occasions and six subjects received TZ (2."( Repeated administration of diazepam and triazolam to subjects with histories of drug abuse.
Griffiths, RR; Roache, JD, 1986
)
0.54
" Blood samples were obtained immediately before dosing and at selected times up to 12 hours after dosing."( Temporal variation in triazolam pharmacokinetics and pharmacodynamics after oral administration.
Kroboth, PD; Phillips, JP; Smith, RB, 1986
)
0.59
" The mean total area under the curve for sublingual administration was significantly larger than that following oral dosage (28."( Enhanced bioavailability of triazolam following sublingual versus oral administration.
Friedman, H; Greenblatt, DJ; Scavone, JM; Shader, RI, 1986
)
0.57
" This study used nocturnal polysomnography and daytime sleep/wake tendency measures (Multiple Sleep Latency Test, MSLT) to assess the efficacy and safety of a reduced triazolam dosage (0."( Efficacy of a reduced triazolam dose in elderly insomniacs.
Roehrs, T; Roth, T; Wittig, R; Zorick, F, 1985
)
0.78
" It is concluded that both active drugs were highly effective, with a minimum of side effects, in this type of insomnia and with the relatively low dosage used."( Triazolam (Halcion) versus flunitrazepam (Rohypnol) against midwinter insomnia in Northern Norway.
Bratlid, T; Lingjaerde, O, 1981
)
1.71
" The efficacy appeared to remain constant after establishing the optimum dosage for every patient."( [Long term utilisation (six months) of an hypnotic triazolobenzodiazepine (triazolam) by psychiatric patients].
Floris, M,
)
0.36
" The study provides further evidence of the lack of change in pharmacokinetic parameters on multiple dosing and that drug accumulation did not occur."( Pharmacokinetics of triazolam in geriatric patients.
Abrahamsson, L; Björnson, G; Börjesson, L; Dehlin, O; Smith, RB, 1983
)
0.59
" The maximal dosage was 8 capsules per day (2."( Studies on the dependence-inducing potential of zopiclone and triazolam.
Boissl, K; Delmotte, M; Dreyfus, JF, 1983
)
0.51
" During long term administration alprazolam should therefore take longer to reach steady-state concentrations in obese patients but the final levels achieved should be no different than for patients of normal bodyweight, provided dosage is adjusted for ideal rather than total bodyweight."( The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam.
Abernethy, DR; Divoll, M; Greenblatt, DJ; Shader, RI; Smith, RB,
)
0.36
" The maximal dosage was 8 capsules per day (2."( Studies on the dependence-inducing potential of zopiclone and triazolam.
Boissl, K; Delmotte, M; Dreyfus, JF, 1982
)
0.5
" for 14 days) the corresponding dose-response lines were shifted to the right suggesting tolerance development."( Subacute benzodiazepine treatment: observations on behavioural tolerance and withdrawal.
Gonzalez, JP; McCulloch, AJ; Nicholls, PJ; Sewell, RD; Tekle, A, 1984
)
0.27
" The rate and extent of accumulation during multiple dosage depend on elimination half-life and clearance."( [Benzodiazepines: significance of kinetics for therapy].
Ochs, HR, 1983
)
0.27
" Of the subject ratings, next day ratings obtained on the day after dosing resulted in significant correlations whereas same day ratings obtained while subjects were under the influence of triazolam did not."( Reinforcing effects of triazolam in sedative abusers: correlation of drug liking and self-administration measures.
Henningfield, JE; Jaffe, JH; Klein, S; Meisch, RA; Roache, JD; Sampson, A, 1995
)
0.79
" Pharmacodynamic changes were significantly intercorrelated; all effects were maximal 1 to 2 hours after dosage but were indistinguishable from placebo by 8 hours."( Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies.
Gouthro, TA; Greenblatt, DJ; Harmatz, JS; Locke, J; Shader, RI, 1994
)
0.55
" Dose-response curves for the two drugs were not parallel, and therefore, comparisons of the two drugs were based upon comparisons of the high dose of each drug."( Differential effects of triazolam and ethanol on awareness, memory, and psychomotor performance.
Bennett, RH; Cherek, DR; Cowan, KA; Roache, JD; Schenkler, JC, 1993
)
0.59
" Chronic oral dosing (every 2nd day) with triazolam (0."( Tolerance to the anxiolytic effects of the triazolobenzodiazepines triazolam and alprazolam, as measured by the ingestion of a hypertonic sodium chloride solution in rats.
Barbarito, EJ; Falk, JL; Lau, CE, 1996
)
0.79
" Data from 6 of 12 subjects in this study were evaluable because of a dosing error in the other 6 subjects."( Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment.
Barbhaiya, R; Chaikin, PC; Folan, MM; Kroboth, PD; Lush, RM; Salazar, DE; Shukla, UA, 1995
)
0.29
" If triazolam is coadministered with nefazodone, a reduction in the triazolam dosage is recommended; no dosage adjustment is required for nefazodone."( Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam.
Barbhaiya, RH; Greene, DS; Kroboth, PD; Shukla, UA, 1995
)
1.07
" The dependence of this interaction on the time interval of their ingestion and the possibility of avoiding the interaction by a correct daily dosing was studied."( The effect of ingestion time interval on the interaction between itraconazole and triazolam.
Neuvonen, PJ; Olkkola, KT; Varhe, A, 1996
)
0.52
", type of insomnia, type of physician who prescribed the drug) variables; (2) to estimate the proportion of long-term users (> 3 mo); (3) to determine the frequency of different administration schedules; (4) to determine whether the kind of hypnotic drug prescribed according to the duration of its effect correlates with the type of sleep disorder or patient age; and (5) to compare the dosage used by the elderly with that used by adults."( Hypnotic drug use in Spain: a cross-sectional study based on a network of community pharmacies. Spanish Group for the Study of Hypnotic Drug Utilization.
Alvarez, C; DeAbajo, FJ; del Barrio, H; Madurga, M; Montero, D; Palop, R; Rayón, P; Serrano-Castro, M, 1996
)
0.29
" In both groups the dosage taken by most patients, regardless of the drug, corresponded to the available strength."( Hypnotic drug use in Spain: a cross-sectional study based on a network of community pharmacies. Spanish Group for the Study of Hypnotic Drug Utilization.
Alvarez, C; DeAbajo, FJ; del Barrio, H; Madurga, M; Montero, D; Palop, R; Rayón, P; Serrano-Castro, M, 1996
)
0.29
" Most patients are taking hypnotic drugs daily, over long time periods, and without an adequate dosage titration according to age."( Hypnotic drug use in Spain: a cross-sectional study based on a network of community pharmacies. Spanish Group for the Study of Hypnotic Drug Utilization.
Alvarez, C; DeAbajo, FJ; del Barrio, H; Madurga, M; Montero, D; Palop, R; Rayón, P; Serrano-Castro, M, 1996
)
0.29
"A case of repetitive hallucinations during treatment with a therapeutic dosage of triazolam (0."( Hallucinations after a therapeutic dose of benzodiazepine hypnotics with co-administration of erythromycin.
Kaneko, S; Kondo, T; Mihara, K; Morita, S; Otani, K; Tokinaga, N, 1996
)
0.52
" Blood samplings were performed up to 48 h after alprazolam dosing and up to 12 h after triazolam dosing."( Relationship between single oral dose pharmacokinetics of alprazolam and triazolam.
Furukori, H; Hayashi, K; Kaneko, S; Nagasaki, T; Ohkubo, T; Otani, K; Sugawara, K; Tasaki, H; Yasui, N, 1997
)
0.75
" There were no significant differences in plasma concentrations from 20 minutes to 6 hours after the dosing nor in pharmacokinetic parameters of triazolam between the EM and PM groups."( Single-dose pharmacokinetics and pharmacodynamics of oral triazolam in relation to cytochrome P4502C19 (CYP2C19) activity.
Chiba, K; Ishizaki, T; Kaneko, S; Ohkubo, T; Osanai, T; Otani, K; Sugawara, K; Yasui, N, 1997
)
0.74
" Dosage assignment was random and double blind."( Side effects of triazolam in children.
Awamura, K; Coldwell, SE; Depner, KS; Karl, HW; Kaufman, E; Milgrom, P; Preston, KL,
)
0.48
"030-mg/kg triazolam dosage impaired visual acuity and stereoscopic depth perception."( Side effects of triazolam in children.
Awamura, K; Coldwell, SE; Depner, KS; Karl, HW; Kaufman, E; Milgrom, P; Preston, KL,
)
0.88
"This study evaluated a cumulative dosing procedure for drug discrimination with human participants."( Comparing single and cumulative dosing procedures in human triazolam discriminators.
Bickel, WK; Smith, BJ, 1999
)
0.55
" All three benzodiazepines were susceptible to drug interactions, but oral dosing of midazolam and triazolam resulted in greater alterations in the pharmacokinetic parameters than alprazolam due to their larger presystemic extraction."( Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam.
Balian, JD; Flockhart, DA; Yuan, R, 1999
)
0.73
" For example, human terfenadine hepatic extraction goes from 95% in the absence of a competitive inhibitor to 35% in the presence of one (ketoconazole, 200 mg po Q 12 h dosed to steady-state)."( Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general.
Boxenbaum, H,
)
0.13
" Flumazenil produced a mild or intermediate precipitated-withdrawal syndrome on day 14 of all dosing conditions."( Zaleplon and triazolam physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons.
Ator, NA; Griffiths, RR; Kaminski, BJ; Kautz, MA; Weerts, EM, 2000
)
0.68
" Panadiplon pretreatment resulted in leftward shifts in the pentobarbital dose-response function but predominantly rightward shifts of the triazolam dose-response function."( Discriminative stimulus effects of panadiplon (U-78875), a partial agonist at the benzodiazepine site, in pentobarbital-trained rhesus monkeys.
Rowlett, JK; Woolverton, WL, 2001
)
0.51
"25 mg (1) alone, (2) on the third day of dosing ranitidine 75 mg twice daily for 4 days, and (3) on the third day of dosing ranitidine 150 mg twice daily for 4 days."( Effect of ranitidine on the pharmacokinetics of triazolam and alpha-hydroxytriazolam in both young (19-60 years) and older (61-78 years) people.
Kersey, K; Koch, KM; Lam, R; O'Connor-Semmes, RL; Williams, DH, 2001
)
0.57
"Rhesus monkeys responding under a multiple fixed ratio (FR:FR) schedule of food presentation and stimulus-shock termination received GABA(A) modulators under cumulative dosing procedures."( The negative GABA(A) modulator methyl beta-carboline-3-carboxylate attenuates the behavioral effects of the positive GABA(A) modulators triazolam and pregnanolone in rhesus monkeys.
France, CP; McMahon, LR, 2001
)
0.51
"Establishing functional deficits as a result of neurotoxic dosing regimens of MDMA has been difficult."( Effects of fenfluramine, m-CPP and triazolam on repeated-acquisition in squirrel monkeys before and after neurotoxic MDMA administration.
Delatte, MS; McCann, UD; Moerschbaecher, JM; Ricaurte, GA; Stevenson, MW; Winsauer, PJ; Yuan, J, 2002
)
0.59
" Column chromatography methodology was developed to separate lopinavir from ritonavir starting from the commercially available lopinavir-ritonavir combination dosage form."( Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir.
Greenblatt, DJ; Harmatz, JS; Hesse, LM; Richert, C; von Moltke, LL; Weemhoff, JL, 2003
)
0.32
" Triazolam, meprobamate, and butabarbital showed comparable negative dose-response slopes on the objective measures."( Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital.
Busto, UE; Greenblatt, DJ; Kaplan, HL; Sellers, EM; Zawertailo, LA, 2003
)
1.46
", dose-response curves for the drugs alone and in combination) and behavioral arrangements (e."( Behavioral and physiological effects of cocaine in humans following triazolam.
Baker, RW; Haga, JL; Rush, CR, 2003
)
0.55
" A supplemental dosage equal to half the initial dose was necessary for 10% of patients and was administered 30 minutes after the initial dose if there was no evidence of sedation."( Triazolam use in the dental setting: a report of 270 uses over 15 years.
Donaldson, M; Quarnstrom, FW,
)
1.57
" TRIAZ lacked the inverted U-shaped dose-response relationship with NR usually seen with DIAZ."( Anxiolytic-like action in mice treated with nitrous oxide and oral triazolam or diazepam.
Condouris, GA; Gries, DA; Houpt, M; Shey, Z, 2005
)
0.56
" Subjects memorized the word and nonword lists 1 h before dosing and they were asked to recall the memorized lists 10 h after dosing."( Zolpidem and triazolam do not affect the nocturnal sleep-induced memory improvement.
Boric, K; Cárdenas, AM; Galli, I; Henríquez-Roldán, CF; Meléndez, J; Ortega, A; Zuñiga, L, 2005
)
0.7
" Recent anecdotal reports suggest that incremental sublingual dosing of triazolam may be an effective technique for producing conscious sedation in the dental setting."( Pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers.
Heacox, GA; Jackson, DL; Kharasch, ED; Milgrom, P, 2006
)
0.81
" Besides the availability of inherently safe drugs, pulse oximetry, and emergency equipment, conservative dosing guidelines should be established for the oral medications used most commonly."( Calculating and justifying total anxiolytic doses of medications for in-office use.
Donaldson, M; Goodchild, JH,
)
0.13
" Most medications available for OCS are used in an "off-label" manner and have no determined maximum recommended dosage for that purpose."( Maximum cumulative doses of sedation medications for in-office use.
Donaldson, M; Goodchild, JH,
)
0.13
" This study sought to assess the safety of individualized dosing of enteral sedation for adults in the dental outpatient setting."( Evidence of safety for individualized dosing of enteral sedation.
Dionne, RA; Gordon, SM; Shimizu, N; Shlash, D,
)
0.13
"Incremental sublingual (SL) dosing of triazolam has emerged as a popular sedation technique."( Flumazenil reversal of sublingual triazolam: a randomized controlled clinical trial.
Heima, M; Hosaka, K; Jackson, D; Milgrom, P; Pickrell, JE, 2009
)
0.9
"Deep sedation from incremental SL dosing of triazolam is incompletely reversed by a single intraoral injection of flumazenil."( Flumazenil reversal of sublingual triazolam: a randomized controlled clinical trial.
Heima, M; Hosaka, K; Jackson, D; Milgrom, P; Pickrell, JE, 2009
)
0.89
" This laboratory study evaluated the hypothesis that incremental dosing of triazolam produces dose-dependent central nervous system depression that is profound and long lasting."( Expanded studies of the pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers.
Heima, M; Hosaka, K; Jackson, DL; Kharasch, E; Milgrom, PM; Pickrell, JE, 2009
)
0.81
" Eighteen guinea pigs were divided into three dosage groups (10, 100, and 500 microg/kg) and administrated a single dose of triazolam intragastrically."( Determination of triazolam and alpha-hydroxytriazolam in guinea pig hair after a single dose.
Shen, B; Shen, M; Sun, Q; Xiang, P; Yan, H, 2010
)
0.91
" Results were compared with the effects of lyophilized GFJ and commercially-available powdered grapefruit capsules, which may be more convenient dosage forms."( Grapefruit juice, lyophilized grapefruit juice, and powdered whole grapefruit inhibit cytochrome P450-mediated triazolam hydroxylation by beagle dog liver microsomes.
Cerundolo, R; Court, MH; Hanley, MJ; Radwanski, N, 2010
)
0.57
" Although separating their dosages by 24 hours has been shown to reduce the interaction, an appropriate dosage interval remains to be determined."( Pharmacokinetic modeling of the dosing interval dependency for the interaction between itraconazole and triazolam.
Ohtani, H; Sawada, Y; Toi, A; Tsujimoto, M, 2010
)
0.58
" Subsequently, we simulated the plasma concentration profiles of triazolam administered after itraconazole therapy with various dosing intervals."( Pharmacokinetic modeling of the dosing interval dependency for the interaction between itraconazole and triazolam.
Ohtani, H; Sawada, Y; Toi, A; Tsujimoto, M, 2010
)
0.81
"The model could explain and simulate the interaction between itraconazole-triazolam using a variety of dosage intervals between the administrations."( Pharmacokinetic modeling of the dosing interval dependency for the interaction between itraconazole and triazolam.
Ohtani, H; Sawada, Y; Toi, A; Tsujimoto, M, 2010
)
0.81
" We evaluated the inductive effect of rifampicin (RIF), a typical human PXR ligand, on the plasma exposure to the four P450 substrate drugs (triazolam/CYP3A4, pioglitazone/CYP2C8, (S)-warfarin/CYP2C9, and (S)-(-)-mephenytoin/CYP2C19) by cassette dosing in PXB mice."( Investigation of drug-drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver.
Hasegawa, M; Inoue, R; Kakuni, M; Tahara, H; Tateno, C; Ushiki, J, 2012
)
0.58
" Dosing AST-120 at least 30 min before triazolam administration may avoid these interactions."( Effects of dosing interval on the pharmacokinetic and pharmacodynamic interactions between the oral adsorbent AST-120 and triazolam in humans.
Imai, H; Kotegawa, T; Morita, H; Morita, M; Namiki, N; Ohashi, K; Ohyama, T; Tsutsumi, K; Uchida, S; Watanabe, H; Yoshizato, T, 2012
)
0.86
" From the dose-response functions, ED50s (i."( Differential interactions engendered by benzodiazepine and neuroactive steroid combinations on schedule-controlled responding in rats.
Gunter, BW; Platt, DM; Rowlett, JK, 2015
)
0.42
" In this study, the next-day residual effects of zolpidem, triazolam, and rilmazafone, following bedtime dosing in elderly subjects, were evaluated."( Residual effects of zolpidem, triazolam, rilmazafone and placebo in healthy elderly subjects: a randomized double-blind study.
Ito, W; Kanbayashi, T; Nishino, S; Satake, M; Shimizu, K; Shimizu, T; Shioya, T; Uemura, SI; Wakasa, M, 2015
)
0.95
"Rhesus monkeys (n=4) were trained under a progressive-ratio schedule of intravenous midazolam delivery and dose-response functions were determined for triazolam, in the absence and presence of flumazenil (non-selective antagonist), βCCT and 3-PBC (α1GABAA-preferring antagonists), and XLi-093 (α5GABAA-selective antagonist)."( Antagonism of triazolam self-administration in rhesus monkeys responding under a progressive-ratio schedule: In vivo apparent pA2 analysis.
Cook, JM; Fischer, BD; Namjoshi, OA; Platt, DM; Rallapalli, SK; Rowlett, JK, 2016
)
0.99
"Flumazenil, βCCT and 3-PBC shifted the dose-response functions for triazolam to the right in a surmountable fashion, whereas XLi-093 was ineffective."( Antagonism of triazolam self-administration in rhesus monkeys responding under a progressive-ratio schedule: In vivo apparent pA2 analysis.
Cook, JM; Fischer, BD; Namjoshi, OA; Platt, DM; Rallapalli, SK; Rowlett, JK, 2016
)
1.03
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
sedativeA central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
triazolobenzodiazepineAny organic heterotricyclic compound that is any benzodiazepine which is ortho-fused with a triazole.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (35)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency27.83810.000221.22318,912.5098AID743035; AID743054; AID743063
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency26.83250.000214.376460.0339AID720692
pregnane X nuclear receptorHomo sapiens (human)Potency15.84890.005428.02631,258.9301AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency27.31440.000229.305416,493.5996AID743079; AID743080; AID743091
aryl hydrocarbon receptorHomo sapiens (human)Potency33.49150.000723.06741,258.9301AID743085
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency14.96010.001723.839378.1014AID743083
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency0.79430.00798.23321,122.0200AID2551
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency33.49150.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency33.49150.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Ki1.04340.00020.656110.0000AID40376; AID40377
Gamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)Ki0.00080.00000.21085.6234AID72927
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Ki1.04340.00020.656110.0000AID40376; AID40377
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Ki1.04340.00020.656110.0000AID40376; AID40377
Gamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)Ki2.00090.00000.18819.0000AID71266; AID72927; AID73089; AID73244; AID73523
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Ki1.04340.00020.561410.0000AID40376; AID40377
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki0.00080.00010.739610.0000AID40377
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Ki1.04340.00020.635210.0000AID40376; AID40377
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Ki1.04340.00020.621710.0000AID40376; AID40377
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Ki1.04340.00020.675810.0000AID40376; AID40377
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Ki1.04340.00020.646910.0000AID40376; AID40377
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Ki1.04340.00020.656110.0000AID40376; AID40377
Gamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)Ki2.00090.00010.20769.0000AID71266; AID72927; AID73089; AID73244; AID73523
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Ki1.04340.00020.656110.0000AID40376; AID40377
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Ki1.04340.00020.671210.0000AID40376; AID40377
Cholecystokinin receptor type ARattus norvegicus (Norway rat)IC50 (µMol)39.00000.00000.43624.3000AID52421
Gamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)Ki0.00150.00010.24425.6234AID73523
Gamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)Ki0.00140.00010.25155.6234AID73244
Gamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)Ki0.00060.00010.24015.6234AID73089
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Ki1.04340.00020.557710.0000AID40376; AID40377
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Ki1.04340.00020.640310.0000AID40376; AID40377
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Ki1.04340.00020.570810.0000AID40376; AID40377
Gamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)Ki10.00000.00020.41199.0000AID71266
Cholecystokinin receptor type ACavia porcellus (domestic guinea pig)IC50 (µMol)39.00000.00041.13803.5000AID52421
GABA theta subunitRattus norvegicus (Norway rat)Ki1.04340.00020.656110.0000AID40376; AID40377
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Ki1.04340.00020.656110.0000AID40376; AID40377
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)Kd0.00100.00010.01020.0760AID343089
Gamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)Kd0.00400.00050.12830.8260AID343090
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (36)

Processvia Protein(s)Taxonomy
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
post-embryonic developmentGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
adult behaviorGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
roof of mouth developmentGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
behavioral fear responseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
associative learningGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
inner ear receptor cell developmentGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
innervationGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
cochlea developmentGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (19)

Processvia Protein(s)Taxonomy
GABA receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
identical protein bindingGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
signaling receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (31)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
axonGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
nucleoplasmGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
cytosolGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
neuronal cell body membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
presynaptic membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
axonGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synaptic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
neuronal cell bodyGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
inhibitory synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
cerebellar Golgi cell to granule cell synapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (202)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1150961Anxiolytic activity in ip dosed male albino CF-1 mouse assessed as decrease in traction reflex1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and pharmacology of novel anxiolytic agents derived from 2-[(dialkylamino)methyl-4H-triazol-4-yl] benzophenones and related heterocyclic benzophenones.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID520313Inhibition of CYP3A activity in orally dosed human2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir.
AID40377Binding affinity for Diazepam sensitive (DS) isoform of the benzodiazepine (Bz) binding site on GABAA receptors1993Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13
Synthetic and computer-assisted analysis of the structural requirements for selective, high-affinity ligand binding to diazepam-insensitive benzodiazepine receptors.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1137415Reduction of hypoxic stress in ip dosed albino CF1 mouse assessed as prolongation of hypoxic survival time1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1218479Drug metabolism in human liver microsomes assessed as 100 uM clarithromycin-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID648851Binding affinity to PCAF assessed as change in melting temperature at 10 uM by protein stability shift assay2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1150967Anxiolytic activity in ip dosed male albino CF-1 mouse assessed as inhibition of pentylenetetrazole-induced clonic convulsions1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and pharmacology of novel anxiolytic agents derived from 2-[(dialkylamino)methyl-4H-triazol-4-yl] benzophenones and related heterocyclic benzophenones.
AID52421Displacement of [125I]CCK from Cholecystokinin receptor of rat pancreas1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Cholecystokinin antagonists. Synthesis and biological evaluation of 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID648847Binding affinity to BAZ2B assessed as change in melting temperature at 10 uM by protein stability shift assay2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1218483Drug metabolism assessed as 1.24 uM docetaxel-mediated inhibition of human CYP3A4-mediated metabolite formation by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID131571Sedative activity was determined by measuring the inhibition of spontaneous motor activity1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Amino acid amide derivatives of 2-[3-(aminomethyl)-4H-1,2,4-triazol-4-yl]benzophenones, a novel class of annelated peptidoaminobenzophenones.
AID1150963Anxiolytic activity in ip dosed male albino CF-1 mouse assessed as inhibition of nicotine-induced tonic extensor convulsions1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and pharmacology of novel anxiolytic agents derived from 2-[(dialkylamino)methyl-4H-triazol-4-yl] benzophenones and related heterocyclic benzophenones.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID224348Inhibition of PAF-induced platelet aggregation in rabbit platelet rich plasma1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
Analogues of platelet activating factor. 8. Antagonists of PAF containing an aromatic ring linked to a pyridinium ring.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID343090Binding affinity to GABAA alpha-5-beta-2-gamma-2 receptor2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Selective influence on contextual memory: physiochemical properties associated with selectivity of benzodiazepine ligands at GABAA receptors containing the alpha5 subunit.
AID1218489Drug metabolism assessed as 100 uM chloramphenicol-mediated inhibition of human CYP3A4-mediated metabolite formation by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID224180Concentration required to inhibit PAF (5*10e-8 M) induced platelet aggregation in rabbit platelet rich plasma(PRP) by 50%1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
Analogues of platelet activating factor. 7. Bis-aryl amide and bis-aryl urea receptor antagonists of PAF.
AID1218484Drug metabolism assessed as 10 uM ritonavir-mediated inhibition of human CYP3A4-mediated metabolite formation by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1218487Drug metabolism assessed as 100 uM clarithromycin-mediated inhibition of human CYP3A4-mediated metabolite formation by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1150962Anxiolytic activity in ip dosed male albino CF-1 mouse assessed as decrease in dish reflex1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and pharmacology of novel anxiolytic agents derived from 2-[(dialkylamino)methyl-4H-triazol-4-yl] benzophenones and related heterocyclic benzophenones.
AID648857Binding affinity to BRD2-BD2 assessed as change in melting temperature at 10 uM by protein stability shift assay2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
AID128826Antianxiety activity was determined by measuring the antagonism of foot shock induced fighting (taming) in mice1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Amino acid amide derivatives of 2-[3-(aminomethyl)-4H-1,2,4-triazol-4-yl]benzophenones, a novel class of annelated peptidoaminobenzophenones.
AID648846Binding affinity to BRDT-BD1 assessed as change in melting temperature at 10 uM by protein stability shift assay2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
AID1137418Inhibition of oxotremorine-induced hypothermia in ip dosed albino CF1 mouse1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1136387Effect on motor activity in ip dosed albino CF-1 mouse by traction test1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1218485Drug metabolism assessed as 100 uM tamoxifen-mediated inhibition of human CYP3A4-mediated metabolite formation by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID26362Ionization constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1136124Drug level in mouse brain treated with (5-chloro-2-(3,5-dimethyl-4H-1,2,4-triazol-4-yl)phenyl)(2-chlorophenyl)methanamine at 20 mg/kg, ip after 20 mins by GC-MS analysis1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Novel anxiolytic agents derived from alpha-amino-alpha-phenyl-o-tolyl-4H-triazoles and -imidazoles.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID73244Binding affinity for human recombinant gamma-aminobutyric-acid (GABA) A receptor alpha-3-beta-3-gamma-22000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.
AID1218478Drug metabolism in human liver microsomes assessed as 10 uM paclitaxel-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID131573Sedative activity was determined by measuring the loss of the righting reflux induced by thiopental sodium in mice1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Amino acid amide derivatives of 2-[3-(aminomethyl)-4H-1,2,4-triazol-4-yl]benzophenones, a novel class of annelated peptidoaminobenzophenones.
AID1136113Anticonvulsant activity in ip dosed CF-1 albino mouse assessed as antagonism of nicotine-induced tonic extensor convulsions1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Novel anxiolytic agents derived from alpha-amino-alpha-phenyl-o-tolyl-4H-triazoles and -imidazoles.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID73523Binding affinity for human recombinant gamma-aminobutyric-acid (GABA) A receptor alpha-5-beta-3-gamma-22000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID131572Sedative activity was determined by measuring the loss of the righting reflux induced by chlorprothixene in mice1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Amino acid amide derivatives of 2-[3-(aminomethyl)-4H-1,2,4-triazol-4-yl]benzophenones, a novel class of annelated peptidoaminobenzophenones.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID389440Displacement of [3H]flunitrazepam from GABAA benzodiazepine receptor in rat brain membrane2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Axial chirality and affinity at the GABA(A) receptor of pyrimido[1,2-a][1,4]benzodiazepines and related compounds.
AID1136119Anticonvulsant activity in po dosed Sprague-Dawley rat assessed as antagonism of pentylenetetrazole-induced clonic convulsions1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Novel anxiolytic agents derived from alpha-amino-alpha-phenyl-o-tolyl-4H-triazoles and -imidazoles.
AID1136394Anticonvulsant activity in ip dosed albino CF-1 mouse assessed as inhibition of strychnine-induced seizures1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID1136388Effect on motor activity in ip dosed albino CF-1 mouse by chimney test1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID167798Concentration needed to inhibit PAF-induced platelet aggregation in rabbit PRP by 50%1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1136125Drug level in Sprague-Dawley rat brain treated with (5-chloro-2-(3,5-dimethyl-4H-1,2,4-triazol-4-yl)phenyl)(2-chlorophenyl)methanamine at 20 mg/kg, ip after 20 mins by GC-MS analysis1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Novel anxiolytic agents derived from alpha-amino-alpha-phenyl-o-tolyl-4H-triazoles and -imidazoles.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1137414Antidepressant activity in ip dosed albino CF1 mouse assessed as potentiation of gamma-butyrolactone-induced sleep1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity.
AID1136114Anticonvulsant activity in ip dosed CF-1 albino mouse assessed as antagonism of nicotine-induced death1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Novel anxiolytic agents derived from alpha-amino-alpha-phenyl-o-tolyl-4H-triazoles and -imidazoles.
AID129148Anticonvulsant activity was determined as the degree of protection against convulsions induced by pentylenetetrazole in mice1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Amino acid amide derivatives of 2-[3-(aminomethyl)-4H-1,2,4-triazol-4-yl]benzophenones, a novel class of annelated peptidoaminobenzophenones.
AID1218488Drug metabolism assessed as 100 uM troleandromycin-mediated inhibition of human CYP3A4-mediated metabolite formation by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID688286Allosteric modulation of gamma-aminobutyric acid receptor A alpha1beta2gamma2S expressed in Xenopus oocytes assessed as potentiation of GABA-mediated chloride current at 0.1 to 500 uM by voltage clamp analysis relative to control2011Journal of natural products, Aug-26, Volume: 74, Issue:8
Identification and characterization of GABA(A) receptor modulatory diterpenes from Biota orientalis that decrease locomotor activity in mice.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID131236Muscle relaxation was determined by using rotatory drum (rotarod) in mice, activity is expressed as ED50 values1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Amino acid amide derivatives of 2-[3-(aminomethyl)-4H-1,2,4-triazol-4-yl]benzophenones, a novel class of annelated peptidoaminobenzophenones.
AID1218477Drug metabolism in human liver microsomes assessed as 100 uM tamoxifen-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1137417Potentiation of yohimbine toxicity in ip dosed aggregated albino CF1 mouse1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1136110Sedative activity in ip dosed CF-1 albino mouse assessed as muscle relaxation by measuring depression of traction1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Novel anxiolytic agents derived from alpha-amino-alpha-phenyl-o-tolyl-4H-triazoles and -imidazoles.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID648845Binding affinity to BRD4-BD1 assessed as change in melting temperature at 10 uM by protein stability shift assay2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
AID1399089Sedative activity in Balb/c mouse at 9 mg/kg, iv administered via bolus dose measured within 10 secs2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Novel benzodiazepines derivatives as analgesic modulating for Transient receptor potential vanilloid 1.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1137413Anticonvulsant activity in ip dosed albino CF1 mouse assessed as inhibition of bicucullin-induced tonic extensor convulsions1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1136393Anticonvulsant activity in ip dosed albino CF-1 mouse assessed as inhibition of thiosemicarbazide-induced seizures1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1218482Drug metabolism assessed as 1 uM ketoconazole-mediated inhibition of human CYP3A4-mediated metabolite formation by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1136116Anxiolytic activity in ip dosed CF-1 albino mouse assessed as antagonism of electric shock-induced effect1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Novel anxiolytic agents derived from alpha-amino-alpha-phenyl-o-tolyl-4H-triazoles and -imidazoles.
AID40376Binding affinity for Diazepam insensitive (DI) isoform of the benzodiazepine (Bz) binding site on GABAA receptors1993Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13
Synthetic and computer-assisted analysis of the structural requirements for selective, high-affinity ligand binding to diazepam-insensitive benzodiazepine receptors.
AID1218486Drug metabolism assessed as 10 uM paclitaxel-mediated inhibition of human CYP3A4-mediated metabolite formation by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID76083Displacement of [125I]gastrin from guinea pig gastric glands1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Cholecystokinin antagonists. Synthesis and biological evaluation of 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines.
AID1136117Anticonvulsant activity in ip dosed CF-1 albino mouse assessed as antagonism of pentylenetetrazole-induced clonic convulsions1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Novel anxiolytic agents derived from alpha-amino-alpha-phenyl-o-tolyl-4H-triazoles and -imidazoles.
AID233962Ratio of binding affinity against DI Bz receptor to that of DS Bz receptor1993Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13
Synthetic and computer-assisted analysis of the structural requirements for selective, high-affinity ligand binding to diazepam-insensitive benzodiazepine receptors.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1136391Anticonvulsant activity in ip dosed albino CF-1 mouse assessed as inhibition of nicotine-induced seizures1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID648858Binding affinity to BRD3-BD2 assessed as change in melting temperature at 10 uM by protein stability shift assay2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
AID71266Binding affinity for human recombinant gamma-aminobutyric-acid (GABA) A receptor alpha-6-beta-3-gamma-22000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.
AID1150966Anxiolytic activity in ip dosed male albino CF-1 mouse assessed as inhibition of strychnine-induced lethality1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and pharmacology of novel anxiolytic agents derived from 2-[(dialkylamino)methyl-4H-triazol-4-yl] benzophenones and related heterocyclic benzophenones.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1136112Muscle relaxing activity in ip dosed CF-1 albino mouse assessed as depression of dish reflexes1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Novel anxiolytic agents derived from alpha-amino-alpha-phenyl-o-tolyl-4H-triazoles and -imidazoles.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID384956Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Molecular characteristics for solid-state limited solubility.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID648843Binding affinity to BRD2-BD1 assessed as change in melting temperature at 10 uM by protein stability shift assay2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1136111Muscle relaxing activity in ip dosed CF-1 albino mouse by chimney test1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Novel anxiolytic agents derived from alpha-amino-alpha-phenyl-o-tolyl-4H-triazoles and -imidazoles.
AID1218475Drug metabolism in human liver microsomes assessed as 1.24 uM docetaxel-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1137416Inhibition of amphetamine aggregation toxicity in ip dosed albino CF1 mouse compound administered 1 hr prior to challenge measured after 2 hrs1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID1136395Anticonvulsant activity in ip dosed albino CF-1 mouse assessed as inhibition of maximal electric shock-induced seizures1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID1137411Hypothermic activity in ip dosed albino CF1 mouse assessed as effect on body temperature measured after 45 mins1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity.
AID1136396Antidepressant activity in ip dosed albino CF-1 mouse assessed as inhibition of ethanol-induced response1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1150969Anxiolytic activity in ip dosed male albino CF-1 mouse assessed as inhibition of electroshock-induced convulsions1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and pharmacology of novel anxiolytic agents derived from 2-[(dialkylamino)methyl-4H-triazol-4-yl] benzophenones and related heterocyclic benzophenones.
AID73089Binding affinity to human recombinant gamma-aminobutyric-acid (GABA) A receptor alpha-2-beta-3-gamma-22000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.
AID648859Binding affinity to BRD4-BD2 assessed as change in melting temperature at 10 uM by protein stability shift assay2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1218481Drug metabolism in human liver microsomes assessed as 100 uM chloramphenicol-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1136120Retention time of the compound by GLC-electron capture detection analysis1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Novel anxiolytic agents derived from alpha-amino-alpha-phenyl-o-tolyl-4H-triazoles and -imidazoles.
AID1150968Potentiation of ethanol-induced anxiolytic activity in ip dosed male albino CF-1 mouse1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and pharmacology of novel anxiolytic agents derived from 2-[(dialkylamino)methyl-4H-triazol-4-yl] benzophenones and related heterocyclic benzophenones.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID343089Binding affinity to GABAA alpha-1-beta-2-gamma-2 receptor2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Selective influence on contextual memory: physiochemical properties associated with selectivity of benzodiazepine ligands at GABAA receptors containing the alpha5 subunit.
AID1218480Drug metabolism in human liver microsomes assessed as 100 uM troleandromycin-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID1137410Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against pentylenetetrazole-induced clonic convulsions1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1137412Inhibition of apomorphine-induced cage climbing in ip dosed albino CF1 mouse compound administered prior to challenge measured for 5 mins after 5 mins of challenge1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity.
AID648849Binding affinity to LOC93349 assessed as change in melting temperature at 10 uM by protein stability shift assay2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
AID72927Binding affinity for human recombinant gamma-aminobutyric-acid (GABA) A receptor alpha-1-beta-3-gamma-22000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.
AID1136397Anxiolytic activity in ip dosed albino CF-1 mouse under hypoxic stress1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID688292Allosteric modulation of gamma-aminobutyric acid receptor A alpha1beta2gamma2S expressed in Xenopus oocytes assessed as potentiation of GABA-mediated chloride current by voltage clamp analysis2011Journal of natural products, Aug-26, Volume: 74, Issue:8
Identification and characterization of GABA(A) receptor modulatory diterpenes from Biota orientalis that decrease locomotor activity in mice.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1136115Anticonvulsant activity in ip dosed CF-1 albino mouse assessed as antagonism of thiosemicarbazide-induced lethality1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Novel anxiolytic agents derived from alpha-amino-alpha-phenyl-o-tolyl-4H-triazoles and -imidazoles.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1150965Anxiolytic activity in ip dosed male albino CF-1 mouse assessed as inhibition of thiosemicarbazide -induced lethality1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and pharmacology of novel anxiolytic agents derived from 2-[(dialkylamino)methyl-4H-triazol-4-yl] benzophenones and related heterocyclic benzophenones.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID648844Binding affinity to BRD3-BD1 assessed as change in melting temperature at 10 uM by protein stability shift assay2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
AID1218474Drug metabolism in human liver microsomes assessed as 1 uM ketoconazole-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID648848Binding affinity to CREBBP assessed as change in melting temperature at 10 uM by protein stability shift assay2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
AID1137419Potentiation of apomorphine-induced gnawing in ip dosed albino CF1 mouse1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity.
AID1218476Drug metabolism in human liver microsomes assessed as 10 uM ritonavir-mediated inhibition of metabolite formation at 20 uM after 30 mins by LC/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1136390Effect on motor activity in ip dosed albino CF-1 mouse by pedestal test1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID1150964Anxiolytic activity in ip dosed male albino CF-1 mouse assessed as inhibition of nicotine-induced death1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and pharmacology of novel anxiolytic agents derived from 2-[(dialkylamino)methyl-4H-triazol-4-yl] benzophenones and related heterocyclic benzophenones.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID611614Allosteric modulation of gamma-aminobutyric acid receptor A alpha1beta2gamma2S expressed in Xenopus oocytes assessed as potentiation of GABA-mediated chloride current at 1 uM by voltage clamp assay2011Journal of natural products, Jun-24, Volume: 74, Issue:6
Positive GABA(A) receptor modulators from Acorus calamus and structural analysis of (+)-dioxosarcoguaiacol by 1D and 2D NMR and molecular modeling.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1136389Effect on motor activity in ip dosed albino CF-1 mouse by dish test1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1136121Retention time of the compound in mouse brain treated with (5-chloro-2-(3,5-dimethyl-4H-1,2,4-triazol-4-yl)phenyl)(2-chlorophenyl)methanamine at 20 mg/kg, ip after 0.5 hrs by GLC-electron capture detection analysis1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Novel anxiolytic agents derived from alpha-amino-alpha-phenyl-o-tolyl-4H-triazoles and -imidazoles.
AID1136392Anticonvulsant activity in ip dosed albino CF-1 mouse assessed as inhibition of pentylenetetrazole-induced seizures1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID384955Intrinsic aqueous solubility at pH 10 by shake-flask method2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Molecular characteristics for solid-state limited solubility.
AID648850Binding affinity to PB1 assessed as change in melting temperature at 10 uM by protein stability shift assay2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID52403Displacement of [125I]CCK from Cholecystokinin receptor of guinea pig brain1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Cholecystokinin antagonists. Synthesis and biological evaluation of 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1399091Sedative activity in Balb/c mouse at 9 mg/kg, iv administered via bolus dose measured after 44 mins2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Novel benzodiazepines derivatives as analgesic modulating for Transient receptor potential vanilloid 1.
AID1399090Sedative activity in Balb/c mouse at 9 mg/kg, iv administered via bolus dose measured after 8 mins2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Novel benzodiazepines derivatives as analgesic modulating for Transient receptor potential vanilloid 1.
AID1346496Human GABAA receptor alpha3 subunit (GABAA receptors)2000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.
AID1346513Human GABAA receptor alpha5 subunit (GABAA receptors)2000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.
AID1346504Human GABAA receptor alpha2 subunit (GABAA receptors)2000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.
AID1346513Human GABAA receptor alpha5 subunit (GABAA receptors)2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Selective influence on contextual memory: physiochemical properties associated with selectivity of benzodiazepine ligands at GABAA receptors containing the alpha5 subunit.
AID1346520Human GABAA receptor alpha1 subunit (GABAA receptors)2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Selective influence on contextual memory: physiochemical properties associated with selectivity of benzodiazepine ligands at GABAA receptors containing the alpha5 subunit.
AID1346520Human GABAA receptor alpha1 subunit (GABAA receptors)2000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.
AID493017Wombat Data for BeliefDocking2000Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1
Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,187)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990388 (32.69)18.7374
1990's479 (40.35)18.2507
2000's214 (18.03)29.6817
2010's96 (8.09)24.3611
2020's10 (0.84)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 96.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index96.01 (24.57)
Research Supply Index7.42 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index177.27 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (96.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials385 (30.20%)5.53%
Reviews59 (4.63%)6.00%
Case Studies106 (8.31%)4.05%
Observational0 (0.00%)0.25%
Other725 (56.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (13)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Single-center, Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing Oral Sedation to Intravenous Sedation for Ocular Procedures. [NCT03246724]Phase 4327 participants (Actual)Interventional2017-10-16Completed
An Open, Two Period, Two Treatment, Two Sequence, Crossed, Randomized, Single-Dose Study Of Two Oral Preparations Containing 0.25 Mg Of Triazolam (Halcion, Pharmacia & Upjohn S.A. De C.V. Vs. Product Made By Pfizer Pharmaceuticals LLC) In Healthy Voluntee [NCT01017926]Phase 10 participants (Actual)Interventional2010-08-31Withdrawn
Oral Anxiolysis for the Older Pediatric Patient-Which Medication is Preferred? [NCT03360123]4 participants (Actual)Interventional2018-01-26Completed
A Randomized, Single Center, Double-Blind, Multiple-Dose, Placebo-Controlled, Crossover, Double-Dummy Study of The Acute Behavioral and Subjective Effects of Ramelteon in Subjects With a History of Polydrug Abuse. [NCT00671632]Phase 214 participants (Actual)Interventional2003-06-30Completed
A Study to Assess the Sensitivity of Project: EVO Monitor Cognitive Function Measurements to Methylphenidate and Triazolam in Adults 40-55 Years Old [NCT02822937]18 participants (Actual)Interventional2016-07-31Completed
An Open Label, Randomized, Single Dose, Crossover Pivotal Bioequivalence Study of Triazolam Liquid Oral Drops at a Dose of 0.25 Mg Versus Triazolam 0.25 Mg Tablet in Healthy Subjects [NCT01421043]Phase 134 participants (Actual)Interventional2011-09-30Completed
GABA Agonists as Pharmacotherapies for Cocaine Abuse [NCT00218166]Phase 278 participants (Actual)Interventional2001-08-31Completed
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTabs™ in Patients Undergoing an Elective Abdominal Liposuction Procedure [NCT00894699]Phase 240 participants (Actual)Interventional2009-06-30Completed
A Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Subjects [NCT01780259]Phase 158 participants (Actual)Interventional2012-12-31Completed
Physiological, Behavioral and Subjective Effects of Drugs (GHB) [NCT00058955]Phase 120 participants (Anticipated)Interventional2003-08-31Completed
Measurement of the Hippocampal Theta Rhythm From the Outer Ear Canal [NCT03954483]42 participants (Anticipated)Interventional2023-02-14Recruiting
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]Phase 3407 participants (Actual)Interventional2015-01-31Terminated
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, CROSS-OVER, PLACEBO-CONTROLLED, SINGLE DOSE, CLINICAL TRIAL TO ASSESS THE NEXT-DAY RESIDUAL EFFECTS OF GABAPENTIN, DIPHENHYDRAMINE AND TRIAZOLAM ON SIMULATED DRIVING PERFORMANCE IN NORMAL VOLUNTEERS [NCT01888497]Phase 359 participants (Actual)Interventional2013-07-29Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00894699 (1) [back to overview]Summed Richmond Agitation Sedation Score (RASS) Over the 4-hour Study Period (SRS-4)
NCT01888497 (3) [back to overview]Lane Exceedance
NCT01888497 (3) [back to overview]Speed Deviation
NCT01888497 (3) [back to overview]Standard Deviation of Lateral Position (SDLP)
NCT03246724 (5) [back to overview]Anesthesiologist/Certified Registered Nurse Anesthetist (CRNA) Satisfaction
NCT03246724 (5) [back to overview]Number of Participants Requiring Additional Anesthesia Intervention
NCT03246724 (5) [back to overview]Patient Satisfaction
NCT03246724 (5) [back to overview]Surgeon Satisfaction
NCT03246724 (5) [back to overview]Surgical Complication Rates

Summed Richmond Agitation Sedation Score (RASS) Over the 4-hour Study Period (SRS-4)

The primary efficacy endpoint of the study is the sedation level as assessed by the 10-point RASS, where unarousable is graded as minus 5 (- 5) and combative is graded as plus 4 (+ 4). The RASS was assessed at 15 time points throughout the four hour study period. (NCT00894699)
Timeframe: 4 hour study period

Interventionunits on a scale (Least Squares Mean)
Sublingual Sufentanil 15 mcg/Triazolam NanoTab™ 200 mcg-5.44
Placebo NanoTab™0.79

[back to top]

Lane Exceedance

Driving performance assessment for the participants were measured by simulated driving test using Cognitive Research Corporation Driving Simulator (CRCDS-MiniSim). The assessment was performed after 45 minutes of awakening from approximately 6.5 hours of sleep on testing day (after 7.25 hours of study drug administration). Mean lanes excursed/exceeded was reported in the outcome measure. (NCT01888497)
Timeframe: 7.25 hours post-dose

Interventionlanes exceeded (Mean)
Placebo37.8
Gabapentin46.7
Diphenhydramine Citrate52.4
Triazolam147.7

[back to top]

Speed Deviation

Driving performance assessment for the participants were measured by simulated driving test using Cognitive Research Corporation Driving Simulator (CRCDS-MiniSim). The assessment was performed after 45 minutes of awakening from approximately 6.5 hours of sleep on testing day (after 7.25 hours of study drug administration). Standard deviation of speed was reported in the outcome measure. (NCT01888497)
Timeframe: 7.25 hours post dose

Interventionmeters per second (m/sec) (Mean)
Placebo0.9
Gabapentin0.9
Diphenhydramine Citrate1.0
Triazolam1.3

[back to top]

Standard Deviation of Lateral Position (SDLP)

Driving performance assessment for the participants were measured by simulated driving test using Cognitive Research Corporation Driving Simulator (CRCDS-MiniSim). The assessment was performed after 45 minutes of awakening from approximately 6.5 hours of sleep on testing day (after 7.25 hours of study drug administration). SDLP was used to assess driver's ability to track their lane and was the standard deviation of lane positions through the entire drive. (NCT01888497)
Timeframe: 7.25 hours post-dose

Interventioncentimeter (cm) (Mean)
Placebo33.2
Gabapentin34.2
Diphenhydramine Citrate35.4
Triazolam47.4

[back to top]

Anesthesiologist/Certified Registered Nurse Anesthetist (CRNA) Satisfaction

Anesthesiologist/CRNA satisfaction will be determined by completion of a 5 question satisfaction survey. The responses to each question will be graded on a scale from 1 to 6: 1 being the least satisfied and 6 being the most satisfied. After all answers are graded for one survey, they will be averaged to give an overall survey grade on the 1 to 6 scale per anesthesiologist/CRNA. Higher mean scores are associated with higher levels of satisfaction. (NCT03246724)
Timeframe: The anesthesiologist/CRNA satisfaction survey will be administered immediately after the completion of the surgical case.

Interventionscore on a scale (Mean)
Cataract Procedures5.16
Retina Procedures5.14
Cornea Procedures5.33
Glaucoma Procedures4.9

[back to top]

Number of Participants Requiring Additional Anesthesia Intervention

The number of subjects in each arm that received additional anesthetic agents during the operative procedure after the initial sedation. (NCT03246724)
Timeframe: Information regarding additional anesthesia intervention will be collected within 2 days of completion of the subjects surgical procedure.

InterventionParticipants (Count of Participants)
Cataract Procedures11
Retina Procedures8
Cornea Procedures11
Glaucoma Procedures16

[back to top]

Patient Satisfaction

Patient satisfaction will be determined by completion of a 12 question satisfaction survey. The responses to each question will be graded on a scale from 1 to 6: 1 being the least satisfied and 6 being the most satisfied. After all answers are graded for one survey, they will be averaged to give an overall survey grade on the 1 to 6 scale per patient. Higher mean scores are associated with higher levels of satisfaction. (NCT03246724)
Timeframe: The patient satisfaction survey was administered up to two days after surgery.

Interventionscore on a scale (Mean)
Cataract Procedures5.37
Retina Procedures5.23
Cornea Procedures5.37
Glaucoma Procedures5.05

[back to top]

Surgeon Satisfaction

Surgeon satisfaction will be determined by completion of a 5 question satisfaction survey. The responses to each question will be graded on a scale from 1 to 6: 1 being the least satisfied and 6 being the most satisfied. After all answers are graded for one survey, they will be averaged to give an overall survey grade on the 1 to 6 scale per surgeon Higher mean scores are associated with higher levels of satisfaction. (NCT03246724)
Timeframe: The surgeon satisfaction survey will be administered immediately after the completion of the surgery. .

Interventionscore on a scale (Mean)
Cataract Procedures5.28
Retina Procedures5.57
Cornea Procedures5.34
Glaucoma Procedures4.6

[back to top]

Surgical Complication Rates

The number of subjects in each arm that experienced a complication during the operative procedure after the initial sedation. (NCT03246724)
Timeframe: Information regarding surgical complications will be collected within 2 days of completion of the subjects surgical procedure.

InterventionParticipants (Count of Participants)
Cataract Procedures11
Retina Procedures8
Cornea Procedures1
Glaucoma Procedures6

[back to top]